US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

The therapy failed to slow disease progression in patients with early Alzheimer’s in the INVOKE-2 trial (NCT04592874).

I spent four crazy years writing about Cassava Sciences, Adam Feuerstein writes. Yesterday, the story ended exactly as many ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today.Don't Miss our Black ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating ...